A Chica­go biotech skips the IPO in fa­vor of late-stage Se­ries D for a PhI­II Tourette drug

Emalex Bio­sciences has se­cured $250 mil­lion in Se­ries D funds to bankroll a Phase III clin­i­cal tri­al in chil­dren, ado­les­cents and adults who have Tourette syn­drome.

The Chica­go biotech plans to kick off the tri­al this quar­ter and will tar­get 90 sites across the US, Cana­da and Eu­rope with a 220-pa­tient tri­al, which the four-year-old drug de­vel­op­er claims would be the largest transat­lantic tri­al ever for the cen­tral ner­vous sys­tem dis­or­der, chief busi­ness of­fi­cer Er­ic Mess­ner told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER